WHY HAVE MSD & WAYRA UK LAUNCHED VELOCITY HEALTH?

With the NHS facing a funding gap estimated at £30bn by 2020/21, both MSD and Wayra UK believe that we need to look ahead to the future delivery of innovative healthcare solutions.

We want to empower patients to take more control and ownership over their well-being, and believe emerging digital technologies have a vital part to play in achieving this goal.

We believe accelerating healthcare start-ups will help us achieve this and also identify new and sustainable ways of delivering patient care, both now and in the future.

OUR FOCUS FOR 2017

For 2017, Velocity Health will launch two verticals to support start-ups developing technologies that support those living with lifelong health conditions.

Living With and Beyond Cancer will help to support people affected by cancer to self-manage their recovery, while Delivering on Diabetes will aim to improve the treatment and care received by people living with Type 2 Diabetes. Both will aim to increase survivability and the sustainability of healthcare provision.

Living with and Beyond Cancer

NHS England’s Cancer Strategy The independent Cancer Taskforce strategy for the NHS to achieve world-class cancer outcomes by 2020 is set out in NHS England’s Five Year Forward View.

The strategy aims to:
• Prevent as many people from having to experience cancer
• Improve diagnostic pathways so cancer is detected earlier
• Ensure that the most effective treatments are made available, subsequently improving longer-term survival
• Improve the experience and quality of life of people living with and beyond cancer

People affected by cancer – those living with it and those supporting a relative or friend with a diagnosis – are identified as the driving force to change. The Velocity Health MSD call for cancer is focused on people living with and beyond cancer.

NHS England’s focus on technology: Putting technology in the hands of patients, to better enable patients to manage their own healthcare, is at the forefront of NHS England’s technology innovation challenge. Four initiatives have been announced to help facilitate this; a new ‘my NHSE’ website, facilitation of self-diagnosis, patient access to their own health records and greater support for digital apps and wearable technology. NHSE recognises the need for a new approach to how technology can be adopted to meet the needs of patients and the NHS in providing system and healthcare improvements. Harnessing data insights through better sharing of data across the NHS and better access to data for patients will work to improve clinical quality and safety.

Velocity Health/MSD call for Cancer: Living With and Beyond Cancer: We are seeking innovations that will activate people who are surviving with and beyond cancer to self-manage their recovery for long-term survival and sustainability of healthcare provision. What impact does your innovation need to demonstrate? 1. Health and social impact 2. Usability 3. Scalability 4. Value to the Health and Social care system

Delivering on Diabetes

NHS England’s Diabetes Strategy In March 2016, NHS England, Public Health England and Diabetes UK launched the roll-out of the NHS Diabetes Prevention Programme with an ambition to slow the projected growth in incidence of Type 2 diabetes across 27 parts of England. The STP process provides the opportunity for footprints to jointly develop a comprehensive strategy for doing this. Alongside prevention, STPs should consider how to improve outcomes for people with Type 1 and Type 2 diabetes across the clinical pathway by tackling unwarranted variation, and empowering patients through education and community health and wellbeing initiatives. If all GP practices were to achieve at least the national median position for all 3 NICE-recommended treatment targets (for HbA1c, blood pressure, and cholesterol), significant savings and patient benefits would be realised. Increasing the proportion of newly diagnosed diabetes patients attending structured education over the next 5 years could also deliver significant savings and patient benefits by leading to fewer complications.

The strategy aims to:
• Drive a reduction in the projected growth in incidence of diabetes
• Support more people to manage their own care effectively
• Improve treatment and care received

NHS England’s focus on technology: Putting technology in the hands of patients, to better enable patients to manage their own healthcare is at the forefront of NHS Engalnd’s technology innovation challenge. Four initiatives have been announced to help facilitate this; a new ‘my NHSE’ website, facilitation of self-diagnosis, patient access to their own health records and greater support for digital apps and wearable technology. NHSE recognises the need for a new approach to how technology can be adopted to meet the needs of patients and the NHS in providing system and healthcare improvements. Harnessing data insights through better sharing of data across the NHS and better access to data for patients will work to improve clinical quality and safety.

Velocity Health/ MSD call : Delivering on diabetes We are seeking innovations that will improve the treatment and care received by people living with Type 2 Diabetes For example:

• How do we reduce the number of people who have been identified as having Type 2 Diabetes, but are not currently receiving treatment/care?
• How do we improve the treatment of those who are being sub-optimally managed, so that they may live a more full life, whilst also reducing cost-pressures on the health system?
• How can we ensure that people with Type 2 Diabetes are engaged in education and self-management? What impact does your innovation need to demonstrate? 1. Health impact 2. Usability 3. Scalability 4. Value to the Healthcare system

WHAT WE OFFER

Investment

Our acceleration programme will provide funding up to £68,000

Our investor network

Wayra’s investor network helps businesses scale

Office space

The recently refurbished academy provides the perfect location for business growth

Masterclasses

Significant skills development through our ongoing masterclasses

Dedicated mentors

Our mentor network provides helpful guidance throughout the acceleration process

1:1

One-on-one meetings help each start-up develop their businesses more quickly

Coaches

Coaches provide in-depth special advice across different business aspects

Network access

Opportunity to leverage Telefónica and MSD’s global footprint

OUR EXPLORERS NETWORK

Our fundamental Velocity Health principle - ‘All Teach, All Learn’ - means we are continually committed to providing and growing beneficial relationships for our start-ups and the ecosystem.

By creating an extensive network of healthcare professionals, academics, and corporate members, our Velocity Health Explorers Network will have the opportunity to engage with an incredible ecosystem in digital health, whilst also providing entrepreneurs with the right expertise to accelerate their development.

Explorers can join the Velocity Health network by becoming mentors, navigators or collaborators.

VELOCITY HEALTH START-UPS

THE IMPACT OF VELOCITY HEALTH

Quarterly videos on our start-ups.

TERMS & CONDITIONS

View or download the terms and conditions document.

REGISTER YOUR INTEREST FOR THE PROGRAMME

FAQs

Our vision for Velocity Health

MSD, a global healthcare company that is looking to transform healthcare through innovative solutions, and Wayra UK, Telefónica’s digital start up accelerator, are investing in digital innovation in healthcare to address the challenges outlined in the NHS Five Year Forward View. The NHS has a challenge of closing a funding gap that is estimated at £30bn by 2020/21. Meeting this challenge is the responsibility of the NHS, healthcare providers and patients alike and will rely heavily on the skills of those who are placed at the forefront of innovation. We’re challenging the digital start-up community to create solutions that reimagine how healthcare can be delivered in the UK to help improve patient outcomes. We want to do this by nurturing entrepreneurial talent and technological expertise to enable the development of innovative products and services that not only deliver savings and efficiencies to the healthcare system, but will test the capabilities of what’s possible.

Why has Velocity Health selected these two verticals?

MSD is committed to working with the NHS and the clear direction it has laid out in the Five Year Forward View and, more recently, its announcement that it will be looking to fast-track digital excellence and the use of apps and wearables across the NHS. To support the delivery of this vision a new type of partnership will be required. MSD is committed to being a future and meaningful partner in improving how we deliver healthcare, improvements in patient experience, innovations in treatment and making the best use of technology to help us achieve this. We have been working with Wayra to challenge experts in health and technology to provide us with solutions and radical rethinking to bring about substantial change in delivery and patient outcomes.

We have listened to our customers in the patient, clinical and policy environment and believe that we can make a valid contribution in the areas of cancer and diabetes where the burden on our community is profound. We have specific expertise in these areas and understand the complex needs of patients and how changes can have an important effect on their outcomes and the lives of their families and carers. During 2016, MSD challenged the health technology ecosystem to concentrate on prevention and early diagnosis and we will continue to mentor, nurture and support these new entrepreneurs and their solutions in our alumni programme. For 2017, we wanted to mirror the government and policy focus on patient experience and living with these difficult and sometimes devastating conditions and concentrate on how technology can be used to improve health.

Why has MSD launched Velocity Health?

MSD has always worked to tackle some of the biggest unmet health needs of our time and has a proud heritage of R&D and innovation. But we don’t want to stop there – we want to continue to transform healthcare through innovative solutions that go beyond the pill to help form smarter, more flexible and potentially future-proof processes that can help safeguard patients health. Accelerating healthcare start-ups can help provide patients with more access to healthcare, identify new and potentially sustainable ways of delivering preventative care, and, crucially, act as a framework for further innovation. Smaller businesses, by virtue of their size and flexibility, are able to ‘pivot’ and change quickly depending on their circumstance and environment. We believe that we can learn a lot from these entrepreneurs and vice versa so that we can analyse and help shape major emerging and important trends in the industry.

Why are Wayra UK, part of Telefónica Open Future_, involved?

We believe that helping people to stay healthy and reaching out to patients is not just the remit ofthe NHS. Preventing ill-health requires partnerships and our goal will only be met through working closely with the NHS, public, private and third-sector partners to look at the needs of people and how resources can be best used to meet those needs. In this sense, the power of partnership is key in driving innovation forward. In our 150 years, we’ve built long-term, deeply-embedded partnerships with the NHS – who we’ve been working with since its inauguration – academic centres of excellence, and other healthcare providers who believe in creating an environment which thrives for better patient outcomes. Wayra UK also share in that belief.

Wayra is a start-up accelerator that is part of Telefónica Open Future_, a global entrepreneurship and investment network, open to partners. Wayra first launched in Latin America and Spain in 2011 and runs innovation hubs across Europe and Latin America. To date, Open Future_ has invested over 300m euro in 500 businesses and signed 60 partnerships across 17 counties. Wayra in the UK has supported in excess of 140 start-ups, half of which were accelerated through Wayra’s social accelerator programme – the UK’s first accelerator facility for digital technology social ventures. Among those were are number of health-related businesses. From intelligent glasses for the visually impaired, to phone apps identifying possible melanoma, Wayra has created an environment where healthcare start-ups have experienced significant growth and scaled fast. This will significantly increase with the association with Velocity Health.

Who will this benefit?

The benefits will be felt not only by MSD and the new emerging businesses being invested in; the programme will also bring growth to the healthcare sector and the economy with the potential of providing job opportunities, helping differentiate the UK from other innovative healthcare hubs. Ultimately, our aim is to improve the way we deliver care to patients, and hopefully an improved patient experience.

What’s in it for MSD?

We’re looking to run this programme to maximise every opportunity that comes out of Velocity Health. For the start-ups, this means maximising their potential, so they take full advantage of the services on offer as well as the networks that will open up to them. The programme is dependent on their success and our focus will be to ensure they optimise their products and services; build out their teams; attract investment; build credibility; a customer base; enhance their sustainability and scale up fast. In return for the investment made by MSD in partnership with Wayra, MSD will have a right of first negotiation with selected start-up companies. If MSD elects to exercise this right, it will allow MSD to negotiate such reasonable terms that will enable MSD and the start-up to commercialise potential product offerings. There’s opportunity in finding product market fit and sharing value between MSD and the start-ups depending on what problems we need to solve at any one time. The research and innovation potential is very exciting and we can learn a great deal from the start-ups and the process itself. We also envisage using the programme to evoke further entrepreneurship within our own organisation.

Will MSD take equity from the start-up or a share of revenue?

No. However, MSD may exercise the right of first negotiation for potential commercialisation opportunities.

What happens after the acceleration programme ends?

Wayra Wayra UK has an active alumni community, who return each month to provide updates and take full advantage of the networking opportunities available at many of Wayra’s events. They too utilise the academy in Central London to run their own events and hold meetings. It is our belief that those graduating from Velocity Health will go on and make a profound difference and proof-point the potential of what acceleration can do in reimagining healthcare services and delivery. MSD In return for the investment made by MSD in partnership with Wayra, MSD will have a right of first negotiation with selected start-up companies. If MSD elects to exercise this right, it will allow MSD to negotiate such reasonable terms that will enable MSD and the start-up to commercialise potential product offerings. There is also the potential to continue to provide access to our networks locally and globally, which may help in the scalability of the start-up.

Eligibility

  • You must be developing a digital product or service that meets the challenges set. Full definition can be found within the FAQs.
  • 2016 Deadline for submissions is 11:59pm (GMT) on 17th October, 2016.
  • Semi-finals will take place over 8, 9, 10 November, with the finals taking place on Thursday 22nd November.
  • Winners announced at Wayra’s Demo Day in early December.
  • In return for the investment made by MSD in partnership with Wayra, MSD will have a right of first negotiation with selected start-up companies. If MSD elects to exercise this right, it will allow MSD to negotiate such reasonable terms that will enable MSD and the start-up to commercialise potential product offerings.
  • Full terms and conditions can be found within via this link (please ignore deadline dates within this document): https://goo.gl/2AypPB

Reporting Adverse Experiences

To report an adverse experience with a specific MSD product, please call MSD on 01992 467272. You may also report an adverse experience directly to your healthcare provider or to the Medicines and Healthcare products Regulatory Agency (MHRA) directly by visiting https://yellowcard.mhra.gov.uk. Non UK Residents: Countries outside of the United Kingdom may have specific procedures in place to address reports of adverse events.

Please ask your healthcare provider for more information or contact your local health authority.If you have questions relating to MSD prescriptions, your medical conditions or personal health matters, please contact your physician, General Practitioner (GP) or healthcare provider since he or she is most familiar with your medical condition. MSD cannot respond to questions regarding general medical information or information regarding your specific condition.